Iguratimod for the treatment of rheumatoid arthritis in Japan

@article{Tanaka2015IguratimodFT,
  title={Iguratimod for the treatment of rheumatoid arthritis in Japan},
  author={Keiichi Tanaka and Tomonobu Yamaguchi and Masako Hara},
  journal={Expert Review of Clinical Immunology},
  year={2015},
  volume={11},
  pages={565 - 573}
}
Iguratimod (IGU), a small-molecule compound, was developed as a disease-modifying antirheumatic drug in Japan. The pharmacological studies showed that inhibition of the production of cytokines and immunoglobulins mainly contributes to its improvement effect on animal arthritis models. The first clinical study of IGU in Japanese patients with rheumatoid arthritis was started in 1992 and Phase III studies were started in 1998. From the results of Phase II studies, a dose-escalating regimen was… 
Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
TLDR
Iguratimod has good efficacy and tolerance as an additional treatment for rheumatoid arthritis patients with inadequate response to methotrexate and biological disease-modifying anti-rheumatic drugs and its clinical effectiveness and safety are summarized.
Molecular mechanisms and clinical application of Iguratimod: A review.
Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis
TLDR
The evidence suggests that iguratimod may be considered a potential alternative to methotrexate to treat rheumatoid arthritis and future clinical trials in diverse population comparing the efficacy and safety of iguratIMod in monotherapy or combination therapy with DMARDs (other than methotRexate) are warranted.
Clinical Efficacy of Methotrexate Combined with Iguratimod on Patients with Rheumatoid Arthritis and Its Influence on the Expression Levels of HOTAIR in Serum
TLDR
Combination therapy of methotrexate and iguratimod is a safe and effective way to treat RA patients, which can be popularized clinically.
Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage
TLDR
The whole pipeline of immunosuppressive and immunomodulating drugs evaluated in RA is analysed and their mechanisms of action and stage of clinical development are described, with a total of 243 molecules in RA.
Efficacy and safety of combined etanercept and iguratimod for active rheumatoid arthritis
TLDR
Etanercept combined with iguratimod has good safety and remarkable efficacy in treating active rheumatoid arthritis.
Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study
TLDR
IGU add-on therapy can be a therapeutic strategy to achieve remission in RA patients inadequately responding to ≥24-week treatment with bDMARDs, and its effectiveness was assessed.
Iguratimod combination therapy compared with methotrexate monotherapy for the treatment of rheumatoid arthritis: a systematic review and meta-analysis
TLDR
Iguratimod combination therapy produced better results in all the efficacy outcomes than methotrexate monotherapy, and is considered a promising alternative for treating RA.
Biologics in sjögren's syndrome.
Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease
TLDR
Iguratimod can be a therapeutic strategy to achieve remission in relapsed or refractory IgG4-RD patients inadequately responding to corticosteroid treatment with or without other immunosuppressant treatment.
...
1
2
3
4
...

References

SHOWING 1-10 OF 48 REFERENCES
Iguratimod (T-614): A novel disease modifying anti-rheumatic drug
TLDR
Its effectiveness and tolerability comparable to salazosulfapyridine were examined by the clinical trials of Japanese patients with rheumatoid arthritis, and iguratimod is a promising DMARD with novel properties and good clinical response.
Iguratimod: a new disease-modifying antirheumatic drug.
  • H. Mucke
  • Medicine, Biology
    Drugs of today
  • 2012
TLDR
Iguratimod is a welcome addition to the small-molecule drug therapy of rheumatoid arthritis and synergistic in patients with insufficient response to methotrexate and does not significantly increase adverse events.
Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis
TLDR
Iguratimod had significant clinical effects on the RA patients within 24 weeks, and might represent a new practical choice to treat RA patients.
Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study
TLDR
Iguratimod began exhibiting its therapeutic effect within 8 weeks after the initiation of treatment and was effective even in patients who had a poor response to previous treatment with disease-modifying antirheumatic drugs.
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial
TLDR
The study results suggest that iguratimod in combination with MTX was efficacious and had a manageable safety profile and was effective in Japanese patients with active rheumatoid arthritis.
A Novel Disease-Modifying Antirheumatic Drug, Iguratimod, Ameliorates Murine Arthritis by Blocking IL-17 Signaling, Distinct from Methotrexate and Leflunomide
TLDR
It is suggested that iguratimod yields a strong improvement in arthritis via its unique suppression of IL-17 signaling in fibroblast-like synoviocytes, which is different from those of methotrexate and leflunomide.
Long-term safety study of iguratimod in patients with rheumatoid arthritis
TLDR
To use iguratimod safely for a long time, patients should be observed closely for adverse reactions such as increased hepatic enzymes.
Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial
TLDR
Efficacy and tolerance of iguratimod + MTX therapy was maintained to 52 weeks in patients with active RA with inadequate response to MTX in an open-label extension study.
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.
TLDR
Both leflunomide and methotrexate are efficacious for prolonged treatment of RA and this benefit must be weighed against the potential toxicity of this drug when used without folate supplementation.
Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate
TLDR
This 24-week, randomized, double-blind, placebo-controlled trial shows that leflunomide added to ongoing stable-dose methotrexate therapy in patients with persistently active rheumatoid arthritis improves clinical outcomes compared with methot Rexate alone.
...
1
2
3
4
5
...